NCT04528511 BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
| NCT ID | NCT04528511 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai 10th People's Hospital |
| Condition | Atrial Fibrillation New Onset |
| Study Type | OBSERVATIONAL |
| Enrollment | 774 participants |
| Start Date | 2020-10-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 774 participants in total. It began in 2020-10-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.
Eligibility Criteria
Inclusion Criteria: * Adult patients (\>18 years old); * Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization; * Patients must have received in-hospital CEM for at least 5 days; * Patients must give informed consent. Exclusion Criteria: * Patients with a medical history of pre-existing AF; * Patients with a medical history of rheumatic valvular disease; * Patients with a medical history of sick sinus syndrome; * Patients undergoing emergent coronary artery bypass surgery; * Patients who suffer malignant tumors with an expected lifetime less than 1 year ; * Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved; * Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI; * Patients who have died during the index hospitalization.
Contact & Investigator
Yidong Wei, M.D., Ph.D.
PRINCIPAL INVESTIGATOR
Department of Cardiology, Shanghai Tenth People's Hospital
Frequently Asked Questions
Who can join the NCT04528511 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation New Onset. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04528511 currently recruiting?
Yes, NCT04528511 is actively recruiting participants. Contact the research team at messichen@tongji.edu.cn for enrollment information.
Where is the NCT04528511 trial being conducted?
This trial is being conducted at Kaifeng, China, Luoyang, China, Zhengzhou, China, Shanghai, China and 1 additional location.
Who is sponsoring the NCT04528511 clinical trial?
NCT04528511 is sponsored by Shanghai 10th People's Hospital. The principal investigator is Yidong Wei, M.D., Ph.D. at Department of Cardiology, Shanghai Tenth People's Hospital. The trial plans to enroll 774 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.